Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: June 9, 2023

France: These 1 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

DrugPatentWatch® Estimated Loss of Exclusivity Dates in France

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "France: These 1 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" thinkBiotech, 2023
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can JEVTANA KIT (cabazitaxel) generic drug versions launch?

Generic name: cabazitaxel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: France Patent 2,859,996
Patent Title: SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL ET SON PROCEDE DE PREPARATION (New well characterized, crystalline acetone solvate of dimethoxy docetaxel, useful as anticancer and antileukemia agent, obtained by crystallization of dimethoxy docetaxel from aqueous acetone)

JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.